CrossrefInfokarte
A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment
Oncotarget · 2025-07-09 · 16 (1) · 545-558
DOI: 10.18632/oncotarget.28752 ↗Abstract
Kein Abstract verfügbar.
EUVIMED